CytomX Therapeutics (CTMX) EBIT Margin (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly EBIT Margin came in at 191.77% in Q1 2026, down 23620.0% YoY from N/an in Q1 2025, and up 95.45% on a QoQ basis from 4212.97% in Q4 2025.
CytomX Therapeutics (CTMX) EBIT Margin (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of EBIT Margin data on file, last reported at 191.77% in Q1 2026.
- Quarterly EBIT Margin fell 23620.0% year-over-year to 191.77% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 181.92% (down 20629.0% YoY) and the FY2025 annual result came in at 29.35%, down 4745.0% from the prior year.
- EBIT Margin advanced to 191.77% in Q1 2026, from 4212.97% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 46.41% in Q4 2024 to a low of 4212.97% in Q4 2025.
- A 5-year average of 324.05% and a median of 24.06% in 2023 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2023 — EBIT Margin jumped 33061 bps — and 2025, when it sank 425938 bps.
- Tracing CTMX's EBIT Margin over 5 years: stood at 47.25% in 2022, then surged by 95 bps to 2.28% in 2023, then soared by 2138 bps to 46.41% in 2024, then slumped by 9178 bps to 4212.97% in 2025, then surged by 95 bps to 191.77% in 2026.
- The last three EBIT Margin figures came in at 191.77% (Q1 2026), 4212.97% (Q4 2025), and 264.43% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | -1,677.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,677.08% |
| Mar 31, 2026 | -191.77% |
| Dec 31, 2025 | -4,212.97% |
| Sep 30, 2025 | -264.43% |
| Jun 30, 2025 | -6.89% |
| Mar 31, 2025 | 44.43% |
| Dec 31, 2024 | 46.41% |
| Sep 30, 2024 | 12.30% |
| Jun 30, 2024 | -33.65% |
| Mar 31, 2024 | 28.11% |
| Dec 31, 2023 | -2.28% |
| Sep 30, 2023 | 11.84% |
| Jun 30, 2023 | -13.54% |
| Mar 31, 2023 | -24.06% |
| Dec 31, 2022 | -47.25% |
| Sep 30, 2022 | -266.53% |
| Jun 30, 2022 | -233.83% |
| Mar 31, 2022 | -354.67% |
| Dec 31, 2021 | -313.54% |
| Sep 30, 2021 | -337.78% |